MGMT-METHYLATED GLIOBLASTOMA
Clinical trials for MGMT-METHYLATED GLIOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new MGMT-METHYLATED GLIOBLASTOMA trials appear
Sign up with your email to follow new studies for MGMT-METHYLATED GLIOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common drug shield the brain from chemo-radiation damage?
Disease control Recruiting nowThis study tests whether a drug called G-CSF (filgrastim) can help protect brain structure and thinking skills in people with a specific type of glioblastoma (MGMT-methylated). About 60 participants will receive either standard chemoradiation alone or with added G-CSF. The goal i…
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 16, 2026 23:36 UTC
-
New drug cocktail aims to extend life in aggressive brain cancer
Disease control Recruiting nowThis study tests whether adding a second chemotherapy drug (lomustine) to the standard treatment (temozolomide) helps people with a specific type of glioblastoma live longer. The trial includes 200 adults aged 18-70 with newly diagnosed, MGMT-methylated glioblastoma. Participants…
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE3 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 16, 2026 23:35 UTC
-
New hope for brain cancer: experimental virus therapy targets aggressive tumors
Disease control Recruiting nowThis study tests whether adding two experimental drugs, DB107-RRV and DB107-FC, to standard treatment (radiation and chemotherapy) can help people with newly diagnosed high grade glioma, a fast-growing brain cancer. About 70 adults aged 18-75 will receive the drugs during and aft…
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Could a new combo therapy extend life in aggressive brain cancer?
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard treatment (radiation and temozolomide) helps people with newly diagnosed glioblastoma live longer. About 190 adults will be randomly assigned to receive either the standard treatment alone or standard treatment plus…
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC